A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.Scott Kopetz, Natalie Cook, Janet Graham et al.|Journal of Clinical Oncology|2022Cited by 9
37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patientsNatalie Cook, Van K. Morris, J.A. Bridgewater et al.|Annals of Oncology|2024Cited by 5